Dr. Nina Rawal is Partner and Co-Head of Trill Impact Ventures, a leading impact investing house. She previously headed the life science investment team at Industrifonden, a USD 800m VC fund. Previous experience also includes Boston Consulting Group in Stockholm and New York, and VP Strategy and Ventures at Gambro (Baxter Group). She serves on the boards of Cinclus Pharma and Stockholms Sjukhem, a non-profit hospital.
Nina holds a MSc in Biomedicine and a PhD in Molecular Neurobiology, both from the Karolinska Institute with research work done at Columbia University and Hopital la Salpetriere. Recognition for her work includes the selection as a WEF Young Global Leader and a '40 under 40 - European Young Leader.
India and China, produce over half global capacity of COVID-19 vaccines but must improve supply to COVAX – fair distribution is quickest route to recovery.
Lockdowns could have unintended consequences from which poorer nations might not recover. Could countries like Sri Lanka and Malaysia show a better way?